A high-fat diet with vitamin D and propylthiouracil produces a pro-atherogenic phenotype in rats

Abstract

Background: Atherosclerosis begins with dyslipidemia, vascular inflammation, and endothelial dysfunction. Rodent models that capture these early events are needed for mechanistic and interventional studies. This study evaluated whether a cholesterol-rich, high-fat diet (HFD) supplemented with vitamin D and propylthiouracil (PTU) promotes a pro-atherogenic phenotype in rats, as evidenced by dyslipidemia, inflammation, markers of endothelial dysfunction, and early vascular remodeling.

Methods: Male Sprague–Dawley rats (n = 18) received standard chow or a HFD containing 2% cholesterol, 3% lard, 0.5% cholate, vitamin D (200 000 IU/kg), and PTU (0.2% w/w) for 11 weeks. Terminal serum total cholesterol, high-density lipoprotein, low-density lipoprotein (LDL)/very low-density lipoprotein (VLDL), triglycerides, calcium, interleukin-6 (IL-6), C-reactive protein, serum amyloid A (SAA), circulating endothelial nitric oxide synthase (eNOS), and intracellular adhesion molecule-1 (ICAM-1) were measured. The aorta, the coronary arteries, and the liver were examined histologically.

Results: HFD-fed rats developed significant hypercholesterolemia with higher total cholesterol and LDL/VLDL (p < 0.0001) and lower triglycerides (p < 0.0001) versus controls. Serum calcium was higher (p < 0.0001) without vascular calcification. Aortae exhibited wall thickening, smooth-muscle disarray, mononuclear infiltrates, and focal foam cell-like changes; coronary arteries exhibited endothelial irregularities and perivascular infiltrates. Livers exhibited micro- and macrovesicular steatosis. IL-6 and SAA were higher (p < 0.05), and circulating eNOS was lower (p < 0.05); ICAM-1 did not differ significantly.

Conclusion: An 11-week vitamin D/PTU-supplemented HFD induces an LDL-dominant dyslipidemia with systemic inflammation and evidence consistent with endothelial dysfunction, alongside histological features of early vascular remodeling and hepatic steatosis. This nongenetic model may be useful for studying early atherogenic changes.

Keywords

atherosclerosis / dyslipidemia / high-fat diet (HFD) / propylthiouracil (PTU) / rat model

References

[1] Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022; 23(6):3346.

[2] Prasad K, Mishra M. Mechanism of hypercholesterolemia-induced atherosclerosis. Rev Cardiovasc Med. 2022; 23(6):212.

[3] Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr. 2012; 23(4): 222-231.

[4] Shridas P, Tannock LR. Role of serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2019; 30(4): 320-325.

[5] Nishida E, Aino M, Kobayashi SI, et al. Serum amyloid a promotes e-selectin expression via toll-like receptor 2 in human aortic endothelial cells. Mediat Inflamm. 2016; 2016:7150509.

[6] Didion SP. Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. Int J Mol Sci. 2017; 18(12):2563.

[7] Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685-1695.

[8] Livero FADR, Gasparotto Junior A. Non-genetic rats models for atherosclerosis research: from past to present. Front Biosci (Schol Ed). 2019; 11: 203-213.

[9] Liao J, Huang W, Liu G. Animal models of coronary heart disease. J Biomed Res. 2017; 31(1): 3-10.

[10] Patek PR, Bernick S, Ershoff BH, Wells A. Induction of atherosclerosis by cholesterol feeding in the hypophysectomized rat. Am J Pathol. 1963; 42: 137-150.

[11] Gordon CJ. Behavioral and autonomic thermoregulation in the rat following propylthiouracil-induced Hypothyroidism1. Pharmacol Biochem Behav. 1997; 58(1): 231-236.

[12] Andrus SB, Fillios LC, Mann GV, Stare FJ. Experimental production of gross atherosclerosis in the rat. J Exp Med. 1956; 104(4): 539-554.

[13] El Zouka Y, Sheta E, Abdelrazek Salama M, Selima E, Refaat R, Salaheldin Abdelhamid Ibrahim S. Tetrandrine ameliorated atherosclerosis in vitamin D3/high cholesterol diet-challenged rats via modulation of miR-34a and Wnt5a/Ror2/ABCA1/NF-kB trajectory. Sci Rep. 2024; 14(1):21371.

[14] Fan Y, Zhang K. Verbascoside inhibits the progression of atherosclerosis in high fat diet induced atherosclerosis rat model. J Physiol Pharmacol. 2021; 72(3): 329-337.

[15] Ma L, Zhao Z, Zhao Y, Gao Y, Zhao L, Li S. Weizmannia coagulans JA845 improves atherosclerosis induced by vitamin D3 and high-fat diet in rats through modulating lipid metabolism, oxidative stress, and endothelial vascular injury. J Appl Microbiol. 2023; 134(8): 1-9.

[16] Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol. 2000; 20(2): 317-327.

[17] Thorin E, Henrion D, Oster L, et al. Vascular calcium overload produced by administration of vitamin D3 and nicotine in rats. Changes in tissue calcium levels, blood pressure, and pressor responses to electrical stimulation or norepinephrine in vivo. J Cardiovasc Pharmacol. 1990; 16(2): 257-266.

[18] Miao Q, Wang R, Bai D, et al. Antiatherosclerosis properties of total saponins of garlic in rats. Evid Based Complement Alternat Med. 2020; 2020:3683659.

[19] Liu F, Zhu J, Huang Y, et al. Hypolipidemic effect of SR-BI gene delivery by combining cationic liposomal microbubbles and ultrasound in hypercholesterolemic rats. Mol Med Rep. 2013; 7(6): 1965-1969.

[20] Bajwa GS, Morrison LM, Ershoff BH. Induction of aortic and coronary athero-arteriosclerosis in rats fed a hypervitaminosis D, cholesterol-containing diet. Proc Soc Exp Biol Med. 1971; 138(3): 975-982.

[21] Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020; 18(7):e3000410.

[22] Feldman AT, Wolfe D. Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 2014; 1180: 31-43.

[23] Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci. 2017; 24(5): 101-105.

[24] Ma L, Gao Y, Yang G, et al. Notoginsenoside R1 ameliorate high-fat-diet and vitamin D3-induced atherosclerosis via alleviating inflammatory response, inhibiting endothelial dysfunction, and regulating gut microbiota. Drug des Devel Ther. 2024; 18: 1821-1832.

[25] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 139(25): e1082-e1143.

[26] Wang YM, Zhang B, Xue Y, et al. The mechanism of dietary cholesterol effects on lipids metabolism in rats. Lipids Health Dis. 2010; 9:4.

[27] Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48(4): 434-441.

[28] Hassen G, Singh A, Belete G, et al. Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease. Cureus. 2022; 14(5):e25495.

[29] Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand? Clin Diabetes Endocrinol. 2020; 6(1):9.

[30] Kosmalski M, Śliwińska A, Drzewoski J. Non-alcoholic fatty liver disease or type 2 diabetes mellitus-the chicken or the egg dilemma. Biomedicine. 2023; 11(4):1097.

[31] Kakimoto PA, Kowaltowski AJ. Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biol. 2016; 8: 216-225.

[32] Jensen VS, Hvid H, Damgaard J, et al. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague–Dawley rats. Diabetol Metab Syndr. 2018; 10(1): 4.

[33] Højland Ipsen D, Tveden-Nyborg P, Lykkesfeldt J. Normal weight dyslipidemia: is it all about the liver? Obesity (Silver Spring). 2016; 24(3): 556-567.

[34] Christakos S, Li S, De La Cruz J, et al. Vitamin D and the intestine: review and update. J Steroid Biochem Mol Biol. 2020; 196:105501.

[35] de Beer FC, Baltz ML, Munn EA, et al. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology. 1982; 45(1): 55-70.

[36] Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111(12): 1805-1812.

[37] Kalsait R, Khedekar P, Saoji A, Bhusari K. Role of C-reactive protein in the development of atherosclerosis in diet-induced lipidemia in albino rats. Trop J Pharm Res. 2011; 10(1): 41-45.

[38] Gager GM, Biesinger B, Hofer F, et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. Vasc Pharmacol. 2020; 135:106806.

[39] Katkenov N, Mukhatayev Z, Kozhakhmetov S, Sailybayeva A, Bekbossynova M, Kushugulova A. Systematic review on the role of IL-6 and IL-1β in cardiovascular diseases. J Cardiovasc Dev Dis. 2024; 11(7):206.

[40] Mehta NN, deGoma E, Shapiro MD. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2024; 27(1): 12.

[41] den Hartigh LJ, May KS, Zhang XS, Chait A, Blaser MJ. Serum amyloid a and metabolic disease: evidence for a critical role in chronic inflammatory conditions. Front Cardiovasc Med. 2023; 10:1197432.

[42] Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid a induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2008; 295(6): H2399-H2408.

[43] Vallejo A, Chami B, Dennis JM, et al. NFκB inhibition mitigates serum amyloid A-induced pro-Atherogenic responses in endothelial cells and leukocyte adhesion and adverse changes to endothelium function in isolated aorta. Int J Mol Sci. 2018; 20(1): 105.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.